BeOne Medicines Ltd
205 hedge funds and large institutions have $7.3B invested in BeOne Medicines Ltd in 2024 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 90 increasing their positions, 45 reducing their positions, and 35 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 45
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
9% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 35
8% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $13.2M
0% more funds holding
Funds holding: 204 → 205 (+1)
0.12% more ownership
Funds ownership: 3.6% → 3.72% (+0.12%)
10% less capital invested
Capital invested by funds: $8.11B → $7.3B (-$816M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$117M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$52.3M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$28.5M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$23.8M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$23.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$43.4M |
| 2 |
Goldman Sachs
New York
|
-$25.1M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$22.2M |
| 4 |
AI
Axiom Investors
Greenwich,
Connecticut
|
-$15.1M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$11.4M |
ONC Hedge Fund Activity: Q1 2024 in Review
205 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q1 2024, worth a combined $7.3B — down 10% from $8.11B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new ONC positions and 35 closed out — a net gain of 3 holders — while 90 added to existing stakes and 45 trimmed.
The largest buyer was Capital International Investors, adding an estimated $117M. The largest seller was Invesco, cutting an estimated $43.4M.
- 205 institutional investors held BeOne Medicines Ltd (ONC) as of Q1 2024, up from 204 in Q4 2023.
- Funds reported $7.3B of BeOne Medicines Ltd stock for Q1 2024, down 10% quarter-over-quarter.
- 38 funds opened new BeOne Medicines Ltd positions in Q1 2024 and 35 closed out, a net change of +3 holders.
- The largest BeOne Medicines Ltd buyer in Q1 2024 was Capital International Investors, an estimated $117M added.
- The largest BeOne Medicines Ltd seller in Q1 2024 was Invesco, an estimated $43.4M sold.
Based on aggregated 13F filings for Q1 2024.